DNA Sequencing Market (2026 - 2033)

DNA Sequencing Market Summary

The global DNA sequencing market size was valued at USD 17.9 billion in 2025 and is projected to grow from USD 21.7 billion in 2026 to USD 91.9 billion by 2033, growing at a CAGR of 22.9% from 2026 to 2033. The North America market held the largest share of 51.1% of the global market in 2025. The market’s steady growth is driven by rising adoption of next generation sequencing technologies, increasing clinical applications in oncology and rare disease diagnostics, and expanding investments in genomics research globally.

Market Dynamics

Market Concentration & Characteristics

The DNA sequencing industry is characterized by a high degree of innovation, driven by rapid technological advancements, including the adoption of artificial intelligence and machine learning in genomics. Companies are developing innovative solutions by leveraging artificial intelligence, which is expected to drive significant innovation in the industry. For instance, in February 2026, in the U.S., Illumina launched TruPath Genome, a whole-genome sequencing solution that enhanced genomic insight through simplified workflows, improved variant detection, comprehensive gene phasing, and higher-resolution analysis of complex genomic regions.

The DNA sequencing industry is also characterized by a moderate level of merger and acquisition (M&A) activity, driven by the need to strengthen technological capabilities, expand service portfolios, and enhance market presence in a rapidly evolving industry. Leading participants are actively pursuing acquisitions to gain competitive advantages and broaden their geographic reach. For instance, in October 2025, Quintara Biosciences completed the acquisition of Laragen Sanger Sequencing, expanding its sequencing service network in California, ensuring service continuity, and strengthening its presence across the West Coast life sciences market

Regulations influence the market by setting strict standards for accuracy, quality, and safety, which can increase compliance costs and slow product approvals. However, supportive policies such as reimbursement frameworks and national genomic initiatives help boost adoption. Overall, regulation creates both challenges and opportunities, ensuring reliability while promoting wider clinical use of sequencing technologies.

Product expansion is driving the DNA sequencing industry as businesses introduce cutting-edge platforms, improved chemistries, and specialized kits that enhance speed, accuracy, and the range of applications. These developments support broader adoption and overall market growth by providing researchers and clinicians with more adaptable and scalable options.

Numerous businesses are expanding their geographical presence. This strategy enables them to distribute their products and services across various countries. For instance, in April 2022, Illumina, Inc. announced the launch of a cutting-edge Solution Center in São Paulo, Brazil, aligning with the growing interest in clinical genomics and the company's dedication to enhancing global accessibility to genomics in Latin America.

Analyst Perspective

The DNA sequencing market is at a strong growth stage, supported by the increasing adoption of genomics in research, clinical diagnostics, and precision medicine. Significant growth potential remains driven by the rising prevalence of genetic disorders, cancer, and infectious diseases, along with growing investments in genomic research and large-scale sequencing initiatives. Market expansion is increasingly fueled by technological advancements that improve sequencing accuracy, throughput, and cost-efficiency, alongside the broader adoption of next-generation sequencing (NGS) platforms.

In addition, the growing emphasis on personalized medicine, early disease detection, and biomarker-based treatment approaches is expected to support sustained demand for DNA sequencing technologies. As competition intensifies, market participants are expected to focus on product innovation, automation, bioinformatics integration, and geographic expansion to strengthen their market position and capitalize on emerging growth opportunities.

Case Study: PacBio Advances Rare Disease Research Through HiFi Long-Read Sequencing

Background:

Rare diseases collectively affect approximately 1 in 15 people worldwide, with more than 70% of cases having a genetic basis. Despite the use of conventional diagnostic methods such as microarrays, whole-exome sequencing, and short-read whole-genome sequencing, over 50% of rare disease cases remain unresolved due to the inability of these technologies to fully characterize complex genomic regions and structural variants.

Initiative:

PacBio developed and expanded the adoption of its HiFi long-read sequencing technology to improve genomic analysis in rare disease research. The technology enables highly accurate whole-genome sequencing, phased genome assemblies, RNA sequencing, and comprehensive genetic testing, providing deeper insight into complex genomic regions that are often missed by traditional sequencing approaches. The company has also supported large-scale rare disease initiatives through its HiFiSolves program.

Outcome:

HiFi sequencing improved the detection of structural variants, repeat expansions, and other complex genetic alterations, helping researchers achieve higher diagnostic yields and gain a more comprehensive understanding of disease-causing mutations. Technology has supported global efforts to accelerate rare disease diagnosis and advance precision medicine research.

Market Impact:

This case highlights the growing demand for long-read sequencing technologies in the DNA sequencing market. As healthcare providers and researchers seek more accurate solutions for unresolved genetic disorders, adoption of advanced sequencing platforms such as PacBio's HiFi technology is expected to support market growth in rare disease diagnostics and genomic medicine.

Product & Service Insights

Based on product & service, the consumables segment held the largest revenue share of over 48.7% in 2025. The growing accessibility of reagents and kits designed for various library construction stages, including DNA fragmentation, adapter ligation, and quality control, is a key factor in expanding market share. Many of these tools are characterized by simplified and streamlined workflows, pre-prepared components, and compatibility with low-input and formalin-fixed specimens.

The services segment is anticipated to witness the fastest CAGR over the forecast period. Comprehensive data analysis, library preparation, identification & quantification of protein binding sites on DNA, DNA methylation profiles on a genome-wide scale, shotgun sequencing, primer walking sequencing, bacterial artificial chromosome end sequencing, and expressed sequence tags are among the sequencing services available in the market.

Technology Insights

Based on technology, the Next-Generation Sequencing segment held the largest revenue share of over 87.9% in 2025. Continuous technological breakthroughs, along with significant reductions in sequencing time and cost, have made genome sequencing more accurate, accessible, and affordable, driving widespread adoption across research, clinical, and diagnostic applications.

The third-generation sequencing segment is projected to witness the fastest CAGR over the forecast period. By eliminating the need for PCR amplification and incorporating straightforward sample preparation, this technology addresses the limitations of second-generation sequencing while reducing sequencing time and costs. Moreover, this technology can produce long reads longer than many kilobases, which helps to identify repetitive sites in complex genomes and solve assembly problems. Over the forecast period, the advantages of third-generation sequencing are expected to drive growth in this segment.

Workflow Insights

Based on workflow, the sequencing segment held the largest revenue share of over 57.2% in 2025. This step enables the sequencing of the genome and profiling of DNA-protein interactions. It is an integral part of the entire DNA sequencing workflow in research and discovery studies, which accounts for its larger share. The ability of sequencers to generate a large amount of data in a relatively short period accelerates understanding of human health and disease treatments. Moreover, major players such as Illumina, Inc. and Thermo Fisher Scientific, Inc. provide novel platforms for sequencing workflows.

The data analysis segment is projected to record the fastest CAGR during the forecast period, driven by the growing demand for sophisticated tools to handle and interpret the vast amounts of data generated. As whole-genome sequencing adoption increases, demand for robust software for sequence assembly, data processing, and storage continues to grow. To meet this demand, industry participants are introducing new computational platforms aggressively. For instance, in October 2023, PacBio introduced a human whole-genome analysis pipeline. These ongoing software advancements are expected to accelerate segment growth further.

Application Insights

Based on application, the oncology segment held the largest revenue share of over 24.9% in 2025. Technology holds great potential in the field of clinical research, as well as in the development of cancer diagnostics and therapeutics. The value of these technologies in companion diagnostics and precision medicine is widely recognized by clinicians and companies, which is anticipated to propel the segment over the forecast period. NGS is commonly used in oncology, where gene mutations are sequenced and cataloged to develop new cancer diagnoses & treatment methods.

The consumer genomics segment is projected to exhibit the fastest CAGR over the forecast period. Growing personal health awareness and the rising use of paternity testing & genealogy are anticipated to drive the consumer genomics segment, particularly as a DNA sequencing application. Several key market players, including PerkinElmer, Inc., Royal Philips, and Quest Diagnostics, are continually expanding their product portfolios by launching new products in the market, which is expected to further drive segment growth.

End Use Insights

Based on end use, the academic research settings segment held the largest revenue share of over 50.7% in 2025. The demand is supported by extensive genomics research activity, growing funding for large-scale sequencing projects, and widespread adoption of next-generation sequencing technologies across universities and research institutes.

The clinical research segment is expected to register the fastest CAGR, driven by the growing adoption of NGS technologies for high-throughput, parallel gene analysis. NGS enables the efficient screening of multiple gene markers using minimal nucleic acids, making it an ideal tool for clinical applications. Its use in studying tumor heterogeneity, identifying cancer-related genes, and detecting tumorigenic alterations is further expected to accelerate segment growth over the forecast period.

Regional Insights

North America dominated the market with the largest revenue share of 51.1% in 2025. The market demand is driven by strong genomic research infrastructure, widespread use of cutting-edge sequencing technologies, significant investments in precision medicine, and large-scale sequencing projects. For example, in August 2023, Complete Genomics received the “Oscars of Innovation” award for its ultra-high-throughput DNBSEQ-T20×2 sequencer. It is anticipated that such industry recognition for cutting-edge technologies will promote additional innovation and aid in the expansion of regional markets.

U.S DNA Sequencing Market Trends

The U.S. dominates North America’s market due to its extensive research in genomics, oncology, and whole-genome-based studies. Other factors that can be attributed to the significant adoption of DNA sequencing technology in this country are sophisticated research & medical infrastructure, funding, skilled personnel, and companies pushing for better research methods to identify newer technologies for diagnosis & therapies.

Europe DNA Sequencing Market Trends

The Europe market is expected to grow at a significant CAGR during the forecast period, due to the increasing R&D investments and continuous research by scientists which has boosted the demand for innovative NGS solutions.

UK DNA Sequencing Market Trends

The UK DNA sequencing industry is expected to grow rapidly over the forecast period, due to an increase in the development of companion diagnostics and the subsequent establishment of molecular diagnostic development facilities by key market players. Furthermore, ongoing strategic alliances between players in European and Eastern markets are expected to drive market growth during the forecast period in the region. For instance, in June 2025, DeepMind in the U.K. launched AlphaGenome, an AI model designed to predict gene regulation from DNA sequences, enabling non-commercial researchers to assess mutations, generate hypotheses, and design experiments.

Germany DNA Sequencing Market Trends

Germany is positioned as a key market due to its robust biomedical research ecosystem, extensive funding for genomics programs, high adoption of advanced sequencing technologies, and the presence of leading academic and clinical institutions that drive continuous innovation in DNA sequencing applications.

Asia Pacific DNA Sequencing Market Trends

The Asia Pacific is anticipated to witness the fastest CAGR of 26.07% during the forecast period. The regional market is expected to be driven by the ongoing developments in HLA and prenatal NGS testing, coupled with international collaborations with U.S. & European companies. Moreover, the increasing developments in genomics in countries such as Japan and India are expected to support the regional market. For instance, in July 2025, India’s Gujarat State launched the Tribal Genome Sequencing Project, which aims to sequence 2,000 tribal individuals to identify genetic risks, support precision healthcare, and enhance regional genomic research capacity.

China DNA Sequencing Market Trends

China has one of the fastest growing and most advanced DNA sequencing markets, supported by strong government funding, rapid adoption of NGS technologies, expanding clinical applications, and significant investments in large-scale population genomics projects.

Japan DNA Sequencing Market Trends

Japan is expected to see substantial progress, as healthcare and clinical research service providers in the country have been integrating Next-Generation Sequencing (NGS) technologies over the past few years. Ongoing developments in HLA and prenatal NGS testing, coupled with international collaborations with U.S. & European companies, are expected to drive market growth in Japan during the forecast period.

MEA DNA Sequencing Market Trends

The MEA DNA sequencing industry is growing due to rising adoption of NGS for infectious disease monitoring and oncology, increased government investment in precision medicine, and expanding collaborations with global genomic technology providers. For instance, in March 2025, BGI Genomics’ joint venture Genalive secured Saudi Arabia contract from NUPCO for large-scale genetic testing services, expanding precision medicine capabilities across 83 public hospitals, which further supports the regional market expansion.

Kuwait DNA Sequencing Market Trends

In Kuwait, several new genome projects are being launched to sequence underrepresented populations and to understand the genetic variation within the human population. For instance, the Kuwait Genome Project aimed to sequence the individual genomes of the country's population.

Key DNA Sequencing Company Insights

The market is moderately consolidated, led by major players such as Thermo Fisher Scientific, Illumina, Agilent Technologies, QIAGEN, and F. Hoffmann-La Roche Ltd., which maintain strong positions through advanced sequencing platforms, extensive product portfolios, and global distribution networks. Other key participants, including PacBio, BGI, Macrogen, PerkinElmer Genomics, and Eurofins Scientific, are expanding their market presence through innovations in long-read sequencing, bioinformatics, and genomics-based diagnostic services.

Key DNA Sequencing Companies

The following key companies have been profiled for this study on the DNA sequencing market.

• Thermo Fisher Scientific, Inc

• Agilent Technology

• Illumina, Inc.

• QIAGEN

• F. Hoffmann-La Roche Ltd.

• Macrogen, Inc.

• PerkinElmer Genomics

• PacBio

• BGI

• Bio-Rad Laboratories, Inc.

• Myriad Genetics

• PierianDx

• Partek Incorporated

• Eurofins Scientific

Competitive Benchmarking

Recent Developments

• In May 2026, Illumina introduced a whole-genome sequencing-based molecular residual disease (MRD) research solution, enabling highly sensitive cancer detection, genomic profiling, and streamlined five-day workflows on NovaSeq systems for oncology research applications.

"In precision healthcare, early and accurate detection of molecular residual disease is critical to monitoring patients during and after cancer treatment. Illumina's MRD solution for clinical research leverages the advanced sensitivity of whole-genome sequencing, coupled with unparalleled analysis, to enable our customers to more easily deliver the most precise information to advance MRD research. We aim to make WGS in oncology more accessible and scalable to support the integration of precision solutions into the standard of care."

-Todd Christian, senior vice president of Services, Arrays and Genomic Access at Illumina

• In November 2025, Volta Labs in the U.S. launched an expanded Callisto platform, delivering fully automated, multi-chemistry WGS sample preparation with seven validated apps to improve scalability, efficiency, and cross-platform compatibility.

• In July 2025, QIAGEN launched its QIAseq xHYB Long Read Panels in the Netherlands, expanding its NGS portfolio with long-read target enrichment solutions optimized for PacBio systems and complex genomic applications.

• In November 2024, PacBio launched the Vega long-read sequencing platform in the U.S., offering an affordable USD 169,000 benchtop system that delivers HiFi accuracy and expands access to advanced sequencing capabilities. 

DNA Sequencing Market Report Scope

Global DNA Sequencing Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the DNA sequencing market on the basis of product and services, technology, workflow, application, end-use and region:

• Product & Service Outlook (Revenue, USD Million, 2021 - 2033)

  • Instruments

  • Consumables

  • Services

• Technology Outlook (Revenue, USD Million, 2021 - 2033)

  • Sanger Sequencing

  • Next-Generation Sequencing

    • Whole Genome Sequencing (WGS)

    • Whole Exome Sequencing (WES)

    • Targeted Sequencing & Resequencing

  • Third Generation Sequencing

    • Single-Molecule Real-Time Sequencing (SMRT)

    • Nanopore Sequencing

• Workflow Outlook (Revenue, USD Million, 2021 - 2033)

  • Pre-sequencing

  • Sequencing

  • Data Analysis

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Oncology

  • Reproductive Health

  • Clinical Investigation

  • Agrigenomics & Forensics

  • HLA Typing/Immune System Monitoring

  • Metagenomics, Epidemiology & Drug Development

  • Consumer Genomics

  • Others

• End Use Outlook (Revenue, USD Million, 2021 - 2033)

  • Academic Research

  • Clinical Research

  • Hospitals & Clinics

  • Pharmaceutical & Biotechnology Companies

  • Other Users

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • MEA

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

(a) Segment Definition

(b) Estimation Model

Delivered Customizations

This report has been delivered with the following In-depth customizations